Why the study?
Does late treatment with erythropoietin improve left ventricular function and reduce inflammation and oxidative stress in mice with chronic post-MI heart failure?
Does late treatment with erythropoietin improve left ventricular function and reduce inflammation and oxidative stress in mice with chronic post-MI heart failure?
Late treatment with erythropoietin in a mouse model of chronic post-MI heart failure improves left ventricular function and reduces inflammation and oxidative stress via Stat and Akt signaling pathways.
No takes yet. Share an insight, caveat, or question.
Supports EPO investigation in murine post-MI HF; hypothesis-generating and should not yet change practice.
LI et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: